>

Asaf Frumerman - KAMADA Director

<div class='circular--portrait' style='background:#FF9E01;color: white;font-size:3em;padding-top: 40px;;'>KMD</div>
KMDA -- Israel Stock  

ILA 2,071  34.00  1.67%

  Director
Mr. Asaf Frumerman was appointed Director of the Company., effective on November 30, 2017. Mr. Frumerman was a Partner at Brosh Capital since 2013 and was involved with some of the firm largest investments. Prior to Brosh Capital, Mr. Frumerman worked as an analyst at The Dragon Variation Fund and as a consultant at Ernst Young .
  Director Since 2017      
(972) 8 9406472  www.kamada.com

Management Efficiency

The company has accumulated 5.75 M in total debt with debt to equity ratio (D/E) of 4.6 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. KAMADA has Current Ratio of 6.02 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Joseph EldorKADIMASTEM
2018
David GranotPROTALIX BIOTHERAP
2018
Keren TzlillKADIMASTEM
2018
Avner NavehSOLEGREEN LTD
Philip SerlinKITOV PHARMA LTD
2013
Natie ZilberbergSOLEGREEN LTD
2018
Ziv KopEVOGENE LTD
2014
Leah BruckKITOV PHARMA LTD
2016
Amos BarShalevPROTALIX BIOTHERAP
2008
Michael AnghelEVOGENE LTD
2007
Chava ToaffSOLEGREEN LTD
2018
Roger KornbergPROTALIX BIOTHERAP
2008
Hillel RozanskiSOLEGREEN LTD
2018
Shlomo FedidaSOLEGREEN LTD
2018
Shmuel PinchasSOLEGREEN LTD
2010
Steven SteinbergKITOV PHARMA LTD
2016
Lea BloomEVOGENE LTD
2010
Yair AharonowitzCOMPUGEN
2007
Ran TzrorKITOV PHARMA LTD
2017
Adina MakoverKADIMASTEM
2013
Yigal FatranKADIMASTEM
2014

Company Summary

Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. Kamada Ltd. was founded in 1990 and is headquartered in Rehovot, Israel. KAMADA operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 429 people.KAMADA (KMDA) is traded on Tel Aviv Stock Exchange in Israel and employs 429 people.

KAMADA Leadership Team

Pnina Strauss, Vice President - Inhalation programs & IPView
Itzhak Krinsky, DirectorView
Barak Bashari, Vice President - OperationsView
Eran Schenker, Vice President - Medical DirectorView
Tuvia Shoham, Independent DirectorView
Michal Stein, Vice President and Medical Director for ImmunologyView
Shani Dotan, Vice President of Human ResourcesView
Liliana Bar, VP of RandDView
Yael Brenner, Vice President - QualityView
Abraham Havron, Independent DirectorView
Asaf Frumerman, DirectorView
Ruth Wolfson, Senior Vice President - Scientific AffairsView
Shmuel Rubinstein, DirectorView
Naveh Tov, Vice President-Clinical Development and Medical Director for Pulmonary DiseasesView
Michael Berelowitz, DirectorView
David Tsur, Co-Founder and Deputy Executive ChairmanView
Orit Pinchuk, Vice President - Regulatory Affairs and Quality R&DView
Leon Recanati, Chairman of the BoardView
Gil Efron, CFO, Principal Accounting Officer and Deputy CEOView
Jonathan Hahn, DirectorView
Eran Schenkar, Vice President - Medical DirectorView
Gwen Melincoff, DirectorView
Chaime Orlev, Chief Financial OfficerView
Michal Ayalon, Vice President - Research & DevelopmentView
Amir London, Chief Executive OfficerView
Estery GilozRan, Independent DirectorView
Reuven Behar, DirectorView
Eitan Kyiet, Vice President - Business DevelopmentView
Ziv Kop, DirectorView

Stock Performance Indicators

Current Sentiment - KMDA

KAMADA Investor Sentiment

Macroaxis portfolio users are evenly split in their trading attitude regarding investing in KAMADA. What is your trading attitude regarding investing in KAMADA? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish
Skip

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Stocks Correlation. Please also try ETF Directory module to find actively-traded exchange traded funds (etf) from around the world.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page